Cadence Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Cadence Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-56,238	Closed	-$1.12M	–	686
2015 Q4	$1.12M	Buy	56,238 +4,280	+8%	+$81.3K	0.08%	269
2015 Q3	$905K	Sell	51,958 -15,679	-23%	-$319K	0.06%	313
2015 Q2	$1.37M	Buy	67,637 +19,767	+41%	+$381K	0.08%	322
2015 Q1	$843K	Buy	+47,870	New	+$816K	0.05%	437
2014 Q2	–	Sell	-50,060	Closed	-$931K	–	671
2014 Q1	$931K	Buy	+50,060	New	+$689K	0.04%	452

Other funds holding AMRI

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cadence Capital Management's AMRI Position: Q1 2016 in Review

Cadence Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2016, closing a stake of 56,238 shares — an estimated $1.12M sold.

Cadence Capital Management first reported a position in AMRI in Q1 2014 and held it in 5 quarters. The position peaked at $1.37M in Q2 2015. 141 funds tracked by Wall St. Rank hold AMRI as of Q1 2016.

Cadence Capital Management reported no remaining Albany Molecular Research Inc position as of Q1 2016 after selling out during the quarter.
Cadence Capital Management sold 56,238 Albany Molecular Research Inc shares in Q1 2016, an estimated $1.12M.
Cadence Capital Management first reported a position in Albany Molecular Research Inc in Q1 2014 and held it in 5 quarters.
Cadence Capital Management's Albany Molecular Research Inc position peaked at $1.37M in Q2 2015.
141 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2016.

Based on Cadence Capital Management's 13F filing for Q1 2016, filed 2 May 2016.